Showing 2101-2110 of 5771 results for "".
- 2021 ASCRS Annual Meeting Pushed Back to Augusthttps://modernod.com/news/2021-ascrs-annual-meeting-pushed-back-to-august/2477939/ASCRS announced that it is pushing back its 2021 annual meeting in San Francisco from April to August. “This decision was thoroughly researched and discussed, and when weighed against the risks of possibly losing another meeting to the coronavirus, we felt we had no other alternative
- Topcon Announces the European Launch of MYAH Management Tool for Myopia and Dry Eyehttps://modernod.com/news/topcon-announces-the-european-launch-of-myah-management-tool-for-myopia-and-dry-eye/2477931/Topcon announced it has launched its new MYAH instrument in Europe. MYAH is a management tool for eye care professionals interested in building, managing and growing myopia and dry eye services within their practice or research institution, according to a company news release. The all-in-o
- AsclepiX Therapeutics Announces $35 Million Series A Financinghttps://modernod.com/news/asclepix-therapeutics-announces-35-million-series-a-financing/2477929/AsclepiX Therapeutics announced that it has closed a $35 million Series A financing to fund phase 1/2a clinical trials of AXT107, the company’s lead investigational drug, for the treatment of diabetic macular edema (DME), wet age-related macular degeneration (AMD) and macular edema secondary to r
- Viela Bio Announces FDA Approval of Uplinza (Inebilizumab) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/viela-bio-announces-fda-approval-of-uplinza-inebilizumab-for-the-treatment-of-neuromyelitis-optica-spectrum-disorder-nmosd/2477912/Viela Bio announced the FDA approval of Uplizna (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD). The monotherapy drug is the first and only B cell-depleting antibody approved for the disease. Uplizna is indicated for those who are
- Clearside Biomedical Announces Numerous Presentations at ARVO 2020https://modernod.com/news/clearside-biomedical-announces-numerous-presentations-at-arvo-2020/2477906/Clearside Biomedical announced that multiple oral presentations on Clearside’s pipeline and its proprietary SCS Microinjector targeting the suprachoroidal space (SCS) are available online at the ARVO 2020 Meeting. Due to COVID-19, the ARVO 2020 Annual Meetin
- Tarsus Pharmaceuticals Announces Positive Results of Phase 2a Study for TP-03 to Treat Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-announces-positive-results-of-phase-2a-study-for-tp-03-to-treat-demodex-blepharitis/2477893/Tarsus Pharmaceuticals announced positive results of its phase 2a Mars Study and the release later this month of the results of a phase 2b randomized controlled study. The Mars study demonstrated that the use of TP-03 for 4 weeks was well-tolerated and showed promising efficacy in the treatment o
- Iveric Bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings for GA Secondary to AMDhttps://modernod.com/news/iveric-bio-announces-positive-zimura-18-month-data-supporting-the-12-month-efficacy-findings/2479517/Iveric bio announced positive 18 month results from the company’s first phase 3 clinical trial for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The 18 month data support
- ProQR Announces Expert Perspectives Conference Call Serieshttps://modernod.com/news/proqr-announces-expert-perspectives-conference-call-series/2479518/ProQR Therapeutics, a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, announced that it will launch a series of Expert Perspectives calls to provide an in-depth review of topics related to the company’s pipeline and
- Study: Annual Costs for Diagnostic Tests Up to $25B, Antibody Tests Up to $19Bhttps://modernod.com/news/study-annual-costs-for-diagnostic-tests-up-to-25b-antibody-tests-up-to-19b/2479523/The estimated annual cost for diagnostic testing of COVID-19 will range from $6 billion to $25.1 billion, and the cost for antibody testing could vary from $5.2 billion to $19.1 billion, a new study found, according to a FierceHealthcare
- Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidatehttps://modernod.com/news/johnson-johnson-announces-acceleration-of-its-covid-19-vaccine-candidate/2477889/Johnson & Johnson announced that through its Janssen Pharmaceutical Companies division that it has accelerated the initiation of the phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the tri